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Abstract
Background: Musculoskeletal (MSK) pain from the five most common presentations to primary care (back, neck,
shoulder, knee or multi-site pain), where the majority of patients are managed, is a costly global health challenge.
At present, first-line decision-making is based on clinical reasoning and stratified models of care have only been
tested in patients with low back pain. We therefore, examined the feasibility of; a) a future definitive cluster
randomised controlled trial (RCT), and b) General Practitioners (GPs) providing stratified care at the point-of-
consultation for these five most common MSK pain presentations.
Methods: The design was a pragmatic pilot, two parallel-arm (stratified versus non-stratified care), cluster RCT and
the setting was 8 UK GP practices (4 intervention, 4 control) with randomisation (stratified by practice size) and
blinding of trial statistician and outcome data-collectors. Participants were adult consulters with MSK pain without
indicators of serious pathologies, urgent medical needs, or vulnerabilities. Potential participant records were tagged
and individuals sent postal invitations using a GP point-of-consultation electronic medical record (EMR) template.
The intervention was supported by the EMR template housing the Keele STarT MSK Tool (to stratify into low,
medium and high-risk prognostic subgroups of persistent pain and disability) and recommended matched
treatment options. Feasibility outcomes included exploration of recruitment and follow-up rates, selection bias, and
GP intervention fidelity. To capture recommended outcomes including pain and function, participants completed
an initial questionnaire, brief monthly questionnaire (postal or SMS), and 6-month follow-up questionnaire. An
anonymised EMR audit described GP decision-making.
Results: GPs screened 3063 patients (intervention = 1591, control = 1472), completed the EMR template with 1237
eligible patients (intervention = 513, control = 724) and 524 participants (42%) consented to data collection
(intervention = 231, control = 293). Recruitment took 28 weeks (target 12 weeks) with > 90% follow-up retention
(target > 75%). We detected no selection bias of concern and no harms identified. GP stratification tool fidelity
failed to achieve a-priori success criteria, whilst fidelity to the matched treatments achieved “complete success”.
Conclusions: A future definitive cluster RCT of stratified care for MSK pain is feasible and is underway, following key
amendments including a clinician-completed version of the stratification tool and refinements to recommended
matched treatments.
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Background
Musculoskeletal (MSK) pain from common conditions
such as back pain and osteoarthritis are costly global
health challenges, particularly for primary care where the
majority of patients are managed. For example, in the UK,
common MSK problems such as back, shoulder, knee and
multi-site pain account for 14% of General Practitioner
(GP) consultations [1] and estimates from the most recent
global burden of disease studies suggest they are the lead-
ing cause of disability adjusted life years (DALYs) [2, 3].
Given the ageing population and the increasingly complex
and multi-morbid clinical presentations of patients, clin-
ical decision-making is becoming more challenging [4–6].
In addition, consultation rates for MSK pain are increas-
ing, for example in the UK, GP consultations for MSK
pain have increased by 19% (from 310 to 370 million per
year) over a five-year period [7, 8].
Randomised controlled trials (RCTs) show that non-
pharmacological interventions such as physiotherapist-
led supervised exercise and cognitive behavioural
approaches are more effective than minimal usual care
[9–12], yet most guidelines [13–15] lack clarity about
which patients should be offered these additional
interventions [16–18]. At present, primary care decision-
making for MSK pain is mostly based on ruling out
serious pathology and using clinical reasoning without
formal stratification tools to decide on treatment. Asses-
sing the severity, impact and prognosis of individual
patients can be difficult in short primary care consulta-
tions and patient access to other treatments is often
variable [19–22]. Offering everyone consulting in pri-
mary care with MSK pain further treatments is both un-
necessary and impractical [16, 17]. Therefore, finding
ways to better identify which patients to de-medicalise
by limiting care primarily to reassurance and self-
management whilst conversely identifying which patients
should be offered more intensive and expensive health-
care treatments, is an international priority [14, 17, 23].
We have previously demonstrated the clinical- and
cost-effectiveness of a stratified primary care approach
to support clinical decision-making for patients with low
back pain in the UK [24–26]. This approach combines
prognostic stratification (using the STarT Back tool that
classifies individuals into either a low, medium or high
risk subgroup for persistent low back pain-related dis-
ability) with recommended matched treatments for each
subgroup [27–29]. This approach to stratified care for
low back pain has since been recommended in several
international clinical guidelines [30–32]. Whilst low back
pain is the most common MSK pain presentation in pri-
mary care, it accounts for only 26% of the MSK caseload
[1], and it is unknown whether a similar prognostic ap-
proach to stratified care would benefit the large volume
of patients with MSK pain in other body sites/locations
(e.g. knee or shoulder pain).
Given the results of several systematic reviews showing
consistent prognostic factors across MSK pain conditions
[33–37], we developed and validated a single prognostic
stratification tool, the Keele STarT MSK tool, for use
among patients with the five most common MSK pain pre-
sentations in primary care (back, neck, shoulder, knee, and
multi-site pain) [1]. The Keele STarT MSK Tool has shown
good predictive and discriminative ability in development
and validation samples [38], identifying patients at low,
medium or high risk of persistent MSK pain over 6-
months. Using systematic review and consensus methods,
we also agreed evidence-based recommended matched
treatment options for each of the risk subgroups [39, 40].
The STarT MSK stratified primary care intervention
has two components: use of the tool to identify risk sub-
groups, followed by matched treatment options. A de-
finitive trial is needed to test whether this approach is
better for patients’ outcomes and the healthcare system,
compared to usual non-stratified care. Prior to conduct-
ing the main randomised controlled trial (RCT), we
examined the feasibility of a) a future definitive cluster
RCT, and b) GPs using stratified care at the point-of-
consultation. Specific objectives were to:
1) Estimate participant recruitment and follow-up
rates in a pilot cluster RCT
2) Examine evidence of selection bias between trial
arms and participants and non-participants
3) Assess GP fidelity to the stratified care intervention
(use of the stratification tool and matched
treatments) at the point-of-consultation.
4) Conduct secondary descriptive analyses of GP
decision-making and patient self-reported
outcomes.
Methods
Trial design
The study design was a pragmatic, feasibility and pilot,
two-parallel arm (1:1 ratio), cluster RCT in 8 general
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practices, with a nested qualitative study reported separ-
ately [41]. A cluster RCT was chosen over an individual
patient randomisation design as stratified MSK care in-
volves GPs using a slightly different consultation approach
following specific training, as well as the use of a bespoke
electronic medical record (EMR) template, which was only
possible to implement at a practice level without causing a
high probability of intervention contamination across arms
[42]. The units of randomisation were the general practices
and units of observation were adults consulting with MSK
pain. The International Standard Randomised Controlled
Trials Number is ISRCTN15366334.
Participant eligibility criteria and identification
Patients were eligible if, during their visit to a participat-
ing GP practice, the trial’s purpose-built participant
identification screen, embedded within the EMR, was
completed at the point-of-consultation, including GP
confirmation of patient eligibility. Inclusion criteria were:
aged over 18 years, registered at that general practice,
consulting for MSK pain in the back, neck, shoulder,
knee or multi-site pain. The trial identification template
activated automatically for all new or returning episode
cases when GPs (intervention and control) entered one
of over 200 pre-identified MSK Read-codes (i.e. symp-
tom/ diagnostic codes) into the patient’s electronic
medical record (EMR). Exclusions were: clinical indica-
tors of (suspected) serious ‘red flag’ pathology requiring
urgent medical intervention or a known systemic inflam-
matory condition, those unable to communicate in
English (both in reading and speaking), vulnerable
patients including those on the ‘severe and enduring
mental health register’, a diagnosis of dementia or
terminal illness, and recent trauma or bereavement. To
reduce patient/clinician burden, the participant identifi-
cation screen only activated once per patient (providing
it was completed or an exclusion was entered). A further
eligibility criterion, administrated by the research centre,
specified that initial questionnaire responses were com-
pleted within 4 weeks of invitation mailing date (using
self-reported date-of-completion on the questionnaire).
Recruitment
General practices
The UK West Midlands National Institute for Health
Research (NIHR) Clinical Research Network (CRN)
facilitated recruitment of eight general practices who
used the EMIS Web EMR system and collectively
served a target population of > 40,000 adults. GP
practice eligibility criteria included willingness to be
randomised to either stratified care or usual care, to
engage in intervention training (if allocated to strati-
fied care) and to facilitate an anonymised EMR audit
after 6-months in the trial. Practices were also
required to remove any existing MSK stratification
tools (e.g. STarT Back) if they were randomised as a
control practice. Consent to these criteria was sought
through a written agreement with a representative
from each participating practice, prior to randomisa-
tion. We aimed for practices that varied in size, loca-
tion (urban, semi-urban and rural) and population
socio-demographics.
Patients
Patient identification, invitation and recruitment were
facilitated by CRN staff, or practice staff (if preferred),
through a weekly download into a secure mailing data-
base of eligible patients identified from the trial’s IT
identification template. Eligible patients were sent a
study invitation letter and information leaflet, an initial
questionnaire and a consent form with a stamped ad-
dressed envelope to return. A study administrator (blind
to GP practice allocation) was available for telephone
support if required. Signed consent to provide question-
naire outcome data was obtained from all participants
and NHS ethical approval gained (Reference: 16/EM/
0257). Participant recruitment lasted 8 months (October
2016 to May 2017).
Randomisation and blinding
Randomisation used stratified block randomisation
based on GP practice list size to allocate the 8 practices
in a ratio of 1:1 (4 intervention, 4 control). Keele Clinical
Trials Unit (CTU) computer-generated the random se-
quence and ensured concealment by providing each
practice with an anonymised code. Allocation (at cluster
and individual level) was shared with the study team
(except for the trial statistician and outcome data collec-
tors who were blinded until the analysis was finalised).
Blinding for participating GPs was obviously not pos-
sible, however, patients were unaware of the RCT and
the differences between consultations in intervention
and control practices, and instead were informed about,
and consented to, providing questionnaire data for a
study investigating the Treatment of Aches and Pains
(TAPs). These processes follow recommendations for
cluster RCTs [42].
Interventions
Usual care
Patients consulting at the four usual care general practices
received clinical care as usual for MSK pain. Usual pri-
mary care is known to be variable [43–45]; for example,
some patients may receive advice, prescriptions for medi-
cations and nothing more, some may be asked to return
to the GP for follow-up assessment or treatment, whereas
others may be referred to other services, including for
tests and investigations, or treatment services such as
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physiotherapy, orthopaedics or pain clinics. As part of the
trial’s participant identification screen, GPs in control
(and intervention) practices recorded patient’s average
MSK pain intensity (see outcomes section) and primary
MSK pain site at the point-of-consultation on the study
EMR identification template.
Stratified care intervention
The intervention development was based on the Medical
Research Council’s (MRC) framework for the design and
evaluation of complex interventions [46]. To support GPs
in intervention practices to deliver stratified care, we ex-
tended the trial point-of-consultation identification EMR
template to also contain the prognostic stratification tool
(a development version of the Keele STarT MSK tool) -
see Fig. 1 and recommended matched treatment options.
The tool was developed and validated in UK General Prac-
tice to predict persistent pain and disability and allocate in-
dividuals into low, medium or high risk subgroups and is
published elsewhere [38]. The recommended matched
treatment options for each subgroup are provided in Fig. 2
and were developed through a systematic review and ex-
pert consensus process, described in detail elsewhere [39,
40]. In brief, for patients at low risk the treatment options
were restricted to supporting self-management and over-
the-counter medication, discouraging unnecessary investi-
gations or referral. For those at medium risk, they included
referral to conservative non-pharmacological treatments
(e.g. those offered by physiotherapists) and workplace
assessment and advice, and for those at high risk, they
included referral for corticosteroid injections specialist
clinical services (including rheumatology, orthopaedics and
pain clinics), and opioids.
GP training (3–4 h) within intervention practices was
facilitated by an experienced GP trainer (VC) and the
lead author (JH) and included: the rationale for stratified
care, how it differs from usual care, familiarisation with
the EMR template and its fit within the consultation, as
well as addressing any questions or concerns. GPs also
received a training-update half-way through their re-
cruitment period at which feedback data were shared
about individual GP intervention fidelity, with peer-to-
peer comparisons and discussion.
Outcomes measures and analyses
The defined pre-specified measures and success criterion
to address each pilot trial objective were as below, with
no changes once the pilot commenced:
Objective 1
To examine the recruitment and retention rates of
general practices we examined the numbers of expres-
sions of interest, face-to-face introductory meetings
and signed agreements to participate. To examine the
Fig. 1 Development version of the Keele STarT MSK Tool© Keele University
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recruitment and retention rates for individual partici-
pants we examined the numbers of: participant identi-
fication screen activations in the EMR (these were
potentially eligible patients screened by the GP at the
point-of-consultation) and completions (confirmed eli-
gibility and therefore invited by post to participate),
as well as the initial questionnaires returned with
written consent to participate in data collection, and
monthly and 6-month questionnaires returned. Ques-
tionnaire items were examined to identify missing
items and any floor-or-ceiling effects. Means and/or
medians, standard deviations were reported for all the
participant self-reported measures.
The pre-specified success criteria for this objective was
that the trial participant identification screen would be
activated in approximately 2000 consultations leading to
a minimum of 500 participants participating in data col-
lection within an expected 3-month recruitment period
and a follow-up rate of > 75% with less than 5% missing
items in participant questionnaires.
Objective 2
To examine evidence of recruitment selection bias we
descriptively analysed (means and standard deviations
(SD)) the characteristics of intervention and control
arm participants, and characteristics of trial
participants and non-participants, using information
from the EMR participant identification screen at the
point-of-consultation (i.e. MSK pain location, pain in-
tensity, age, sex and deprivation score) and within the
participant self-reported initial questionnaire (demo-
graphic and clinical characteristics, as listed in Add-
itional file 1). The pre-specified success criteria for
this objective was to find little evidence of recruit-
ment selection bias either between intervention and
control participants, and between study participants
and non-participants.
Objective 3
To assess GP fidelity to the stratified care intervention at
the point-of-consultation we examined the proportion of
eligible cases in which GPs used the stratification tool
and choose at least one of the recommended matched
treatments. Per protocol matched treatments for each
subgroup were defined as follows:
– Low risk: must only have low risk treatment options
reported in the EMR
– Medium risk: must have at least one medium risk
treatment option and none of the high risk options
reported in the EMR
Fig. 2 STarT MSK pilot trial recommended matched treatment options
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– High risk: patients must have reported within
the EMR, at least one high risk treatment
option, or a referral to an MSK service providing
a medium risk treatment option (e.g.
physiotherapy or psychological intervention) with
tool subgroup information within their referral
so that services were aware that an onward
referral to a high risk treatment option might be
required.
The pre-specified success criteria for this objective
were that within relevant MSK pain consultations inter-
vention GPs would:
1. Complete the prognostic stratification tool in:
– > 50% of cases: “Complete success” (proceed to main
trial without amendments)
– 40–50% of cases: “Partial success” (proceed to main
trial with amendments)
– < 40% of cases: “Unsuccessful” (consider whether or
not to proceed to main trial)
2. Adhere to per protocol matched treatment options in:
– > 65% of cases: “Complete success” (proceed to main
trial without amendments)
– 50–65% of cases: “Partial success” (proceed to main
trial with amendments)
– < 50% of cases: “Unsuccessful” (consider whether or
not to proceed to main trial)
Objective 4
To examine differences in GP decision-making and
patient self-reported outcomes at the level of inter-
vention and control we conducted secondary descrip-
tive statistical analyses using the anonymised 6-month
EMR audit and follow-up questionnaire data. As this
was a feasibility and pilot trial the objective was not
hypothesis testing of process/health outcomes, there
were no pre-specified success criteria and only
complete cases were analysed.
There were four sources of data:
1. The GP EMR participant identification screen
collected identical point-of-consultation data in all
8 GP practices, including the primary MSK pain
site/location and average pain intensity (intended
primary outcome for the main trial) by asking:
 How intense was your pain, on average, over the last
2 weeks? [Responses on a 0–10 scale, where 0 is “no
pain” and 10 is “worst pain ever”].
Pain intensity was chosen as the potential primary
outcome for the future main trial as it had the stron-
gest face validity with patients during a pre-pilot
Patient and Public Involvement and Engagement
(PPIE) workshop and is also a recommended outcome
for trials testing treatments for MSK pain [47, 48]. In
the intervention practices the EMR participant identi-
fication screen was extended to embed the stratified
care intervention and collect additional data relating
to stratification tool item responses and the matched
treatment options chosen at the point-of-consultation.
All template responses were date stamped and linked
to an individual GP and patient. It was also possible
from the EMR screen to collect automated data on
the MSK consulter’s age, sex and English Index of
Multiple Deprivation (IMD) 2015 [49], with non-
participants data anonymised first.
2. Baseline and 6-month postal questionnaires
included self-reported measures for average pain
intensity over the last 2 weeks (identical wording
and responses to the trial identification template),
physical function measures for each of the MSK
pain sites (filtered according to GP designation)
including the back specific Roland-Morris Dis-
ability Questionnaire (RMDQ) [50], the Neck
Disability Index (NDI) [51, 52] the Shoulder Pain
And Disability Index (SPADI) [53], the Knee In-
jury and Osteoarthritis Outcome Score Physical
Function Short-form (KOOS-PS) [54] and for
multi-site pain, the Short Form 12 (v2) Physical
Component Scale [55]. Other outcomes were
MSK risk status using the development version
of the Keele STarT MSK tool [38], overall MSK
health status using the Musculoskeletal Health
Questionnaire [56], fear avoidance beliefs using
the 11-item Tampa Scale of Kinesiophobia [57],
patient perceived reassurance (from their GP)
using the Effective Consultation and Reassurance
Questionnaire (ECRQ) [58] (which has four sub-
scales: information gathering, relationship build-
ing, generic reassurance and cognitive
reassurance), health-related quality of life using
the EuroQol five-dimension, five-level version
(EQ-5D-5 L) [59], single items each capturing
satisfaction with care received, whether partici-
pants had received written education material
from their GP about their MSK problem (yes/
no), and overall rating of global change (− 5 to +
5 numerical response scale) since their index GP
visit (the one in which the trial EMR screen was
activated and they were invited to participate in
the study data collection) [60], whether they
were in paid employment and had taken any
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work absence due to their MSK pain, and an
item asking how their productivity at work is af-
fected (0–10 NRS). Patient population descriptors
(captured at baseline alone) included; the Single
Item Health Literacy Screener (SILS) [61] and
pain episode duration by asking “how long is it
since you had a whole month without [insert
pain site e.g. back] pain”. Additional file 1 pro-
vides a summary of the self-reported measures
collected.
3. Monthly follow-up
Three items were collected using monthly follow-up
via Short Message System (SMS) text or one-page pos-
tal questionnaire (depending on participant prefer-
ence): average pain intensity (same wording as GP
EMR screen), distress due to pain, and pain self-
efficacy using:
 How much distress have you been experiencing
because of your pain, on average, over the last 2
weeks? [Responses from 0 = no distress to
10 = extreme distress]
 How confident have you felt about managing your
pain by yourself e.g. medication, changing lifestyle?
[Responses from 0 = not at all confident to
10 = extremely confident]
4. Anonymised GP medical record audit
An anonymised audit of medical record data from
all 8 GP practices for patients in whom the trial EMR
participant identification screen had been completed,
including:
i) prescriptions (categorised into simple analgesics,
non-steroidal anti-inflammatories (NSAIDs),
neuromodulators, muscle relaxants, corticosteroid
injections and opioids)
ii) referrals (categorised into physiotherapy/MSK
interface services, secondary care specialist services
including orthopaedics, pain clinics, and
rheumatology)
iii) imaging (categorised into x-rays/MRI scans, MSK
ultrasound scans and bone density scans)
iv) sick certifications or ‘fit-notes’ (categorised into
number per patient and mean length in days)
v) repeat MSK general practice consultations.
Sample size
Whilst sample size calculations for pilot cluster trials
are known to be difficult [62], the initial plan was to
carry out an internal pilot trial with a 3-month
recruitment phase, that mirrored the methods of the
main cluster trial but was limited to assessing feasibil-
ity within 8 GP practices (4 intervention and 4 con-
trol) prior to involvement of a further 22 GP
practices (30 in total). If the internal pilot had
achieved its success criteria, we had planned that
these 8 randomised practices would continue to re-
cruit patients for a full 6-month period, and their
data included in the main trial. Hence, we anticipated
recruiting 500 patients from the 8 practices over the
first 3-months in the internal pilot trial, with a fur-
ther 500 participants to be recruited from those prac-
tices (and in addition 2750 from a further 22
practices for the main trial phase).
Results
Objective 1: general practice and participant recruitment
and retention rates
There were 32 general practices who expressed an
initial interest in participating in the pilot trial from
the West Midlands region of England, of which 16
agreed to a face-to-face introductory meeting with the
research team, and 8 were recruited (with written
agreements) and randomised (4 intervention, 4
control). The reasons given for declining participation
included the practice lacking capacity in terms of
resource at that particular time (n = 2), unwillingness
to participate in the training session (n = 2), unwilling
to use the EMR participant identification screen
(n = 2), being already involved with another MSK pain
research study (n = 1), and a perception that the prac-
tice’s patient population would struggle to respond to
the self-report questionnaires (n = 1). The 8 participat-
ing practices had a total adult practice population size
of 58,307 (25,697 intervention, 32,610 control). The
smallest practice had 3 GPs and a registered adult
population of 3992; the largest had 9 GPs and 13,359
adult patients. In total 59 GPs identified patients for
the trial (39 in control practices and 20 in interven-
tion practices).
Patient recruitment and follow-up through the trial
are described in Fig. 3. Recruitment started on 11/10/
2016 and the last practice template was deactivated on
24/05/2017 with the last invite reminder sent on 21/06/
2017 and last patient provided consent to data collection
on 21/07/2017. There were 3063 potentially eligible
patients screened by GPs at the point-of-consultation,
the EMR participant identification screen was com-
pleted in 1281 with confirmed eligibility, of whom
1237 were actually invited by postal letter to partici-
pate in data collection, 567 initial questionnaires
returned with written consent to participate in data
collection, and 524 responses were received within
the 4-week eligibility time-period (231 intervention
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and 293 controls). To recruit 500 patients took 28
weeks, more than twice as long as the original esti-
mate (12 weeks). Recruitment varied substantially be-
tween the 8 practices (range n = 11–127) suggesting
the need to account for this variation within the main
trial sample size calculation. Once 500 participants
were recruited, the EMR participant identification
screen in practices was switched off, however, we re-
cruited a further 24 participants (n = 524 in total)
over the following month (33 weeks in total) due to
the time lag in sending invitations and receiving pa-
tient consent to data collection (via the post).
The overall participant 6-month follow-up rate for the
intended future RCT primary outcome of pain intensity
was 477/524 (91.0%); usual care 209/231 (90.4%), inter-
vention 268/293 (91.4%). Response rates for monthly
pain intensity scores at 5 or more time-points (max.
Possible was 6) was 82.6%, with data for 3 time-points
available in 91.8%. 15 patients withdrew over the 6
months follow-up period: 5 from intervention practices
Fig. 3 Participant flowchart
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(2 due to illness/surgery/poor health, 1 due to moving
house, and 2 did not want further contact about the
study), and 10 from control practices (5 due to illness/
surgery/poor health, 1 had died (unrelated), 2 withdrew
because they felt recovered, and 2 did not want further
contact). There were no related, unexpected serious
adverse events or harms reported. At 6-month follow-
up patients reported 11 hospital admissions (5 inter-
vention, 6 control) related to their MSK pain (e.g. knee
replacement or shoulder surgery). Missing data items
in the questionnaires remained less than 5%. Anon-
ymised medical record data were available for 1281 pa-
tients (529 from intervention practices and 752 from
control practices).
The success criteria for this objective (the template acti-
vated in approximately 2000 consultations leading to a
minimum of 500 participants providing consent within an
expected 3-month recruitment period and a follow-up rate
of > 75% with less than 5% missing items in patient ques-
tionnaires) was only “partially successful”, as although pa-
tient recruitment and retention were “successful”, the
timeline needed to recruit 500 patients was 28 rather than
12 weeks.
The learning/change needed ahead of the main trial
included reducing the main trial sample size (following
discussion with the independent Trial Steering Com-
mittee and funder) by removing the pre-specified sub-
group analysis (at the risk-subgroup level) and instead
powering the trial for the overall comparison between
intervention and control arms. In addition, the main
trial sample size was re-calculated based on the follow-
ing: Firstly, the pilot recruitment rate showed that the
template was completed in just under 40% of cases, and
from the subsequent letter of invitation 40% returned
their initial questionnaire and provided consent to par-
ticipation in the data collection (on average, 60 patients
per practice). A conservative estimate (50 patients per
practice) was therefore used for the main trial. Sec-
ondly, the proportions expected within each of the
three risk subgroups, as determined from the self-
complete questionnaires, were revised based on the
pilot trial findings, to: 32% low risk, 55% medium risk,
13% high risk. This was important as the trial was pow-
ered to detect superiority of stratified care in the
medium and high risk subgroups, with an expected ef-
fect size of 0.20.
Thirdly, for GP cluster parameterisation, we made the
following estimates, based primarily on previous guide-
lines, as pilot trial figures need to be viewed cautiously
given the possible lack of precision [62]. For the main
trial primary outcome (pain intensity) we have conserva-
tively allowed for an intracluster correlation coefficient
(ICC) of 0.01 based on a guideline from previous
primary care trials [63] and the pilot trial ICC being
considerably lower (0.004). Our main trial estimated co-
efficient of variation in recruitment per practice is also
based on a guideline estimate of 0.65 [64] as well as the
pilot being similar at 0.66. Our expected loss to follow-
up across all time-points is conservatively estimated at
25%, which in the pilot was around 5%. Lastly, our
repeated measures correlation is estimated using a
guideline figure of 0.7 [65], which is conservative based
on our pilot trial figure of 0.65. These factors combine
to give a sample size inflation factor of × 2.3 (based on
an average cluster size of about 50 participants per prac-
tice in 6 months). Correlation of data within 6 repeated
measurements and correlation of follow-up scores with
baseline score are typically 0.7 and 0.5, respectively
which combine to give a sample size deflation factor of
× 0.5). The product of inflation and deflation effects
result in a magnification of 1.15 compared to a conven-
tional, individual-patient, single follow-up comparison,
whereby the sample size requirement would be 525 per
treatment arm (or, 1050 in total). The adjusted sample
size target for the main trial was is therefore 600 patients
per arm (1200 in total) from approx. 24 general practices
(approx. 12 per arm).
Objective 2: to examine evidence of selection bias
Table 1 shows a descriptive evaluation of individual
participant demographics and characteristics (split by
trial arm) and participants and non-participants. Whilst
most characteristics were similar (e.g. sex) between
intervention and control arms suggesting minimal selec-
tion bias, there were a few differences between partici-
pants (e.g. overall, they were slightly older and from
more deprived areas) and non-participants. Mean pain
intensity (0–10 Numerical Response Scale (NRS)) at the
point-of-consultation was similar between participants
(6.33, SD 2.05) and non-participants (6.35, SD 2.10), but
pain scores were 0.5 points higher in participants in the
intervention arm than control, although this difference
had disappeared by the time of the initial patient ques-
tionnaire (typically 1–3 weeks later).
Overall there were few differences across other
characteristics and the pre-specified success criteria
for this objective of finding little evidence of selection
bias was judged “successful”. There were, therefore,
no changes required to recruitment procedures for
the main trial.
Objective 3: assessing GP fidelity to the stratified care
intervention
GPs from intervention practices used the stratification
tool within the EMR in 513/1591 (32%) of eligible
patients, which was “unsuccessful” according to our pre-
specified success criteria. GP fidelity to choosing recom-
mended matched treatment options (shown in Table 2)
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Table 1 Patient baseline characteristics
Key characteristics All participants
(n = 524)
Intervention participants
(n = 231)
Control participants
(n = 293)
Non participants
(n = 713a)
Age, mean (SD) 61.1 (14.8) 60.3 (15.1) 61.8 (14.5) 53.8 (17.8)
Female, n (%) 318 (60.7%) 133 (57.6%) 185 (63.1%) 416 (58.4%)
Index Multiple Deprivation quintile, n (%)
1 (least deprived) 8 (1.5%) 7 (3.0%) 1 (0.3%) 11 (1.6%)
2 55 (10.6%) 17 (7.4%) 38 (13.0%) 102 (14.4%)
3 104 (19.9%) 55 (23.9%) 49 (16.7%) 152 (21.4%)
4 143 (27.3%) 51 (22.2%) 92 (21.4%) 230 (32.4%)
5 (most deprived) 213 (40.8%) 100 (43.5%) 113 (38.6%) 216 (30.4%)
GP Practice, n (%)
A 49 (9.4%) 49 (21.2%) – 84 (11.8%)
B 11 (2.1%) – 11 (3.8%) 17 (2.4%)
C 121 (23.1%) – 121 (41.3%) 197 (27.6%)
D 30 (5.7%) 30 (13.0%) – 23 (3.2%)
E 59 (11.3%) 59 (25.5%) – 76 (10.7%)
F 93 (17.8%) 93 (40.3%) – 99 (13.9%)
G 127 (24.2%) – 127 (43.3%) 168 (23.6%)
H 34 (6.5%) – 34 (11.6%) 49 (6.9%)
Pain location, n (%)
Knee 144 (27.5%) 62 (26.8%) 82 (28.0%) –
Neck 59 (11.3%) 30 (13.0%) 29 (9.9%) –
Back 155 (29.6%) 73 (31.6%) 82 (28.0%) –
Shoulder 124 (23.7%) 53 (22.9%) 71 (24.2%) –
Widespread pain 42 (8.0%) 13 (5.6%) 29 (9.9%) –
Duration (time since whole month
without pain), n (%)
< 3months 136 (26.0%) 69 (29.9%) 67 (22.9%) –
3–6 months 77 (14.7%) 32 (13.9%) 45 (15.4%) –
7–12 months 89 (17.0%) 38 (16.5%) 51 (17.4%) –
1–2 years 75 (14.3%) 30 (13.0%) 45 (15.4%) –
3–5 years 53 (10.1%) 21 (9.1%) 32 (10.9%) –
6–10 years 48 (9.2%) 20 (8.7%) 28 (9.6%) –
> 10 years 46 (8.8%) 21 (9.1%) 25 (8.5%) –
Health Literacy Single Item Screen (Need help),
n (%) [n = 516]
Never/rarely/sometimes 500 (96.9%) 222 (98.3%) 278 (95.9%) –
Often/always 16 (3.2%) 4 (1.8%) 12 (4.2%) –
Comorbidities (No. of listed long-term
conditions), n (%)
–
0 186 (35.5%) 86 (37.2%) 100 (34.1%) –
1 161 (30.7%) 79 (34.2%) 82 (28.0%) –
2 130 (24.8%) 52 (22.5%) 78 (26.6%) –
≥ 3 47 (9.0%) 14 (6.1%) 33 (11.3%) –
Lives alone (Yes), n (%) [n = 523] 87 (16.6%) 40 (17.3%) 47 (16.1%) –
Currently employed (Yes), n (%) [n = 509] 234 (46.0%) 104 (46.6%) 130 (45.5%) –
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Table 1 Patient baseline characteristics (Continued)
Key characteristics All participants
(n = 524)
Intervention participants
(n = 231)
Control participants
(n = 293)
Non participants
(n = 713a)
Pain interference with performance at work
(0–10, the higher score the worse), mean (SD)
4.28 (3.06) [n = 257] 3.87 (2.88) [n = 113] 4.60 (3.16) [n = 144] –
Time-off-work last 6 m due to MSK pain,
n (%) [n = 260]
66 (25.4%) 28 (24.8%) 38 (25.9%) –
Receipt of written information from GP,
n (%) [n = 520]
213 (41.0%) 163 (71.5%) 50 (17.1%) –
Pain intensity (at the point of GP consultation)
(0–10, the higher score the worse), mean (SD)
6.33 (2.05) 6.60 (1.93) 6.11 (2.11) 6.35 (2.10)‡
Pain intensity (self-reported in baseline questionnaire)
(0–10, the higher score the worse), mean (SD)
6.21 (2.25) [n = 523] 6.22 (2.17) [n = 230] 6.21 (2.32) [n = 293] –
Self-efficacy (confidence to manage MSK pain)
(0–10, the higher score the better), mean (SD)
5.43 (2.62) [n = 521] 5.41 (2.67) [n = 228] 5.44 (2.59) [n = 293] –
Distress (0–10, the higher score the worse), mean (SD) 5.66 (2.61) [n = 524] 5.62 (2.60) [n = 231] 5.69 (2.61) [n = 293] –
Days of moderate physical activity per week, median (IQR) 2 (0–4) [n = 521] 2 (0–4) [n = 230] 2 (0–4) [n = 291] –
No. of previous MSK pain episodes, median (IQR) 5 (1–25) [n = 415] 5 (1–15) [n = 186] 5 (1–30) [n = 229] –
MSK Risk status (Keele development version
of the STarT MSK Tool – note it was not the final
version), mean (SD) [n = 482]
–
Low risk (0–3 score), n (%) 155 (32.2%) 67 (30.9%) 88 (33.2%) –
Medium risk (4–7 score), n (%) 263 (54.6%) 119 (54.8%) 144 (54.3%) –
High risk (8–9 score), n (%) 64 (13.3%) 31 (14.3%) 33 (12.5%) –
Overall musculoskeletal health status (MSK-HQ)
(0–56, the higher score the better), mean (SD)
29.6 (10.4) [n = 507] 29.9 (10.5) [n = 223] 29.4 (10.4) [n = 284] –
Overall global change (−5–5, the higher score
the better), mean (SD)
0.34 (2.08) [n = 523] 0.41 (2.19) [n = 230] 0.28 (1.99) [n = 293] –
Fear-avoidance (using 11-item TSK, higher score
the worse) mean (SD)
24.5 (6.80) [n = 511] 24.3 (6.60) [n = 224] 24.7 (6.94) [n = 287] –
Satisfaction with initial GP care [n = 522]
Very satisfied, n (%) 140 (26.8%) 67 (29.1%) 73 (25.0%) –
Quite satisfied, n (%) 184 (35.3%) 81 (35.2%) 103 (35.3%) –
No opinion, n (%) 115 (22.0%) 43 (18.7%) 72 (24.7%) –
Not very satisfied, n (%) 74 (14.2%) 34 (14.8%) 40 (13.7%) –
Not at all satisfied, n (%) 9 (1.7%) 5 (2.2%) 4 (1.4%) –
Patient perceived reassurance from GP for MSK
pain (higher score is better)
Data gathering, mean (SD) 9.9 (4.3) [n = 502] 10.5 (4.6) [n = 223] 9.5 (4.1) [n = 279] –
Relationship building, mean (SD) 11.6 (4.2) [n = 499] 12.0 (4.4) [n = 220] 11.3 (3.9) [n = 279] –
Generic, mean (SD) 13.1 (4.7) [n = 507] 13.2 (5.0) [n = 224] 13.0 (4.5) [n = 283] –
Cognitive, mean (SD) 13.4 (4.7) [n = 510] 13.5 (4.9) [n = 223] 13.2 (4.6) [n = 287] –
Total, mean (SD) 48.0 (16.0) [n = 510] 49.2 (17.2) [n = 224] 47.1 (15.0) [n = 286] –
Knee physical function using KOOS
(the higher score the better), mean (SD)
42.9 (21.2) [n = 142] 44.0 (22.1) [n = 61] 42.0 (20.5) [n = 81] –
Neck physical function using NDI
(the higher score the worse), mean (SD)
16.1 (8.02) [n = 59] 14.6 (6.39) [n = 30] 17.7 (9.28) [n = 29] –
Back physical function using RMDQ
(the higher score the worse), mean (SD)
9.59 (5.50) [n = 155] 9.84 (5.40) [n = 73] 9.38 (5.57) [n = 82] –
Shoulder function using SPADI-Function
(the higher score the worse), mean (SD)
47.1 (24.8) [n = 124] 45.9 (25.3) [n = 53] 48.0 (24.5) [n = 71] –
Multi-site physical function using SF12 PCS 34.4 (9.52) [n = 42] 35.5 (9.35) [n = 13] 33.9 (9.72) [n = 29] –
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Table 1 Patient baseline characteristics (Continued)
Key characteristics All participants
(n = 524)
Intervention participants
(n = 231)
Control participants
(n = 293)
Non participants
(n = 713a)
the higher score the better), mean (SD)
Quality of life using EQ5D-5 L, mean (SD) 0.56 (0.24) [n = 513] 0.55 (0.25) [n = 226] 0.57 (0.22) [n = 287] –
a 43 patients were excluded as they returned their baseline questionnaire after 28 days (17 intervention arm; 26 control arm); 80 baseline responders did not give
full consent to study (39 intervention arm; 41 control arm). Too late and non-consent figures were not mutually exclusive: 9 patients were late and did not
consent to study (3 intervention arm; 6 control arm). Hence, 114 patients were excluded for either lateness or non-consent (53 in intervention arm; 61 in control
arm); 599 patients did not respond (229 in intervention arm; 370 in control arm). ‡ Those in whom the trial template was completed at the point of consultation,
including participants and non-participants
Table 2 GP fidelity to the recommended matched treatment options
Matched GP treatment options Low risk
(n = 161, 38%)
Med risk
(n = 224, 52%)
High risk
(n = 45, 10%)
Grand Total
Advice - verbal 102 63% 108 48% 23 51% 233
Advice - written 91 57% 140 63% 17 38% 248
Advice – over-the-counter medication 84 52% 10 4% 94
Advise GP follow-up if symptoms persist 66 41% 12 5% 78
Refer to Physiotherapy 2 2% 85 84% 14 14% 101
Refer to MSK interface clinic 38 17% 10 22% 48
Refer to pain clinic (multi-disciplinary) 1 0% 3 7% 4
Personalised exercise programme 5 2% 1 2% 6
Refer to Occupational Health support 15 7% 3 7% 18
GP address comorbidity, distress or frailty 1 1% 7 3% 7 16% 15
Prescribe atypical analgesia 2 1% 59 26% 9 20% 70
Prescribe opioids 1 0% 10 22% 11
Signpost to peer support group 2 4% 2
Signpost/refer to lifestyle interventions 2 4% 2
Refer for surgical opinion 3 2% 4 2% 7 16% 14
Corticosteroid injection 1 1% 4 9% 5
Refer to rheumatology 2 1% 1 2% 3
Fidelity to stratified care in decision-making Pt count %
Low risk - per protocol 130 81%
Medium risk - per protocol 200 89%
High risk - per protocol 39 87%
Low risk - given Medium treatments 3 2%
Low risk - given High treatments 3 2%
Medium risk – given Low treatments 0 0%
Medium risk - given High treatment 5 2%
High risk – given Low treatments only 3 7%
High risk – given Medium treatments 0 0%
Low risk – only tool used (no treatments selected) 25 16%
Med risk – only tool used (no treatments selected) 19 8%
High risk – only tool used (no treatments selected) 3 7%
Grand Total 430
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achieved “complete success” with 81% of patients at low
risk, 89% for medium risk and 87% for patients at high risk
being correctly matched to a recommended treatment.
Through the nested qualitative research (reported
separately, [41]) and feedback discussions with the
participating GPs about the reasons for the low rate of
completion of the tool, we gathered a number of insights
to inform the main trial. Firstly, GPs perceived that the
using the whole EMR template increased their consult-
ation workload and asked for the treatment options to
be simplified. They also reported that the stratified care
intervention was only appropriate for consultations
where MSK pain was the primary reason for the consult-
ation, where they could focus on the MSK pain problem.
GPs also admitted that patients had frequently left the
consultation room before they used the EMR and that
they did not use the tool when their clinics were very
busy. We therefore agreed in the future main trial to
lower the expected proportion of MSK related consulta-
tions in which the tool would be used at the point-of-
consultation from 50 to 25%. We also identified that
some GPs rarely coded MSK pain consultations and that
others tended to use ‘Synonym’ codes, which are set of
diagnostic codes that needed to be removed from the list
of codes used to activate the EMR participant identifica-
tion screen, as they caused it to activate in error for a
range of non-MSK pain problems (e.g. chest pain). It
was agreed that for the main trial the GP training
needed to include ways to mitigate these issues. GPs also
recommended reducing the 4 h of intervention training
to 2 h and to provide a dedicated NHS physiotherapy
pathway for patients in the main trial to overcome GPs’
concerns about over-loading physiotherapy services with
patients with MSK pain. Finally, GPs reported feeling
uncomfortable with the self-report style wording of the
development version of Keele STarT MSK tool. For ex-
ample, they felt certain items could be modified to be
less ‘clunky and awkward’ to ask (e.g. item 4: “Do you
have any other important health problems?” which con-
fused/unsettled patients when asked by their own family
doctor who they expected to know their health problems
well). We therefore developed a clinician-completed ver-
sion of the Keele STarT MSK tool for use in the main
trial, to overcome these wording problems, but keeping
the item constructs as similar as possible. A license to
obtain both the original self-report and clinician com-
pleted versions of the tool is available on request at
www.keele.ac.uk/startmsk.
Objective 4: describing GP decision-making and patient
outcomes in both arms
The results from the EMR audit of GP decision-making in
MSK consultations are shown in Table 3 (split by interven-
tion and control). GPs in intervention practices prescribed
less opioids and more over-the-counter medication and
anti-inflammatories than GPs in control practices. In
addition, they gave more written self-management infor-
mation to patients, used less MSK-related imaging and re-
ferred patients to physiotherapy earlier than in control
practices. Numbers of corticosteroid injections, sick certifi-
cations, and repeat MSK pain related general practice con-
sultations over 6months were similar in intervention and
control practices.
Descriptive data on patients’ clinical outcomes over
6-months follow-up are presented in Table 4. Mean
(SD) 6-month pain intensity was 3.93 (2.98) in partic-
ipants in intervention practices and 4.18 (2.88) in
control. Most other 6-month outcomes were similar
although there was less MSK-related time-off-work in
participants from intervention (17.4%) than control
practices (25.4%). We did not statistically compare
these outcomes in this pilot trial.
Discussion
This feasibility and pilot trial examined the feasibility
of a future definitive cluster RCT in respect to re-
cruitment and retention rates, potential selection bias
and GP intervention fidelity to stratified care at the
point-of-consultation for adults with MSK pain.
Our original plan was that this study was an internal
feasibility and pilot trial. Our findings showed that par-
ticipant retention rates were high, that GPs matched pa-
tients to recommended treatment options well (> 80% of
cases), and there was little evidence of selection bias,
therefore the cluster trial design was deemed suitable for
the future main trial. However, the length of time taken
to recruit participants was over twice as long as expected
(28 rather than 12 weeks), and GPs completed the Keele
STarT MSK Tool in fewer patient cases than we had
hoped for (they used it in 32% of patient cases when the
target was > 50%). The nested qualitative study findings
[41] and feedback discussions with participating GPs ex-
plored the reasons why only two of the four pre-
specified pilot trial success criteria were met. These
identified in the particular challenge of using the EMR
template and stratified care intervention when MSK pain
was not the primary reason for the consultation.
GPs also suggested a number of positive changes to
make prior to the future definitive RCT and thus this
study became an external pilot trial. These changes
included simplifying the recommended treatment op-
tions and developing a clinician-completed version of
the Keele STarT MSK Tool. Furthermore, we agreed
to lower the expected proportion of MSK consulta-
tions in whom the tool would be used from 50 to
25% as we were unable to stop the EMR template
from firing in consultations where MSK pain was a
multimorbidity and not the main focus of the
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consultation. We also agreed to give GPs training
specifically about the issue with ‘Synonym’ codes that
failed to activate the EMR participant identification
screen and reduced the intervention GP training from 4 h
to 2 h. Lastly, we organised for NHS physiotherapy
services receiving patients from participating intervention
practices to provide a dedicated pathway for patients in
the main trial. This pathway was put in place to overcome
GPs’ concerns about their referrals over-loading NHS
physiotherapy services with patients with MSK pain and
Table 3 Comparison of GP decision-making between intervention and control practices.
†STarT MSK scored 0–3, low risk; 4–7 medium risk; 8–9 high risk.
The colours represent the effects of the intervention on GP behaviours in comparison to controls:
Reduced (> 0.04) Same Increased (> 0.04) Provided earlier .
“It should be noted that the numbers of patients referred for an x-ray or MRI are combined, as in both the intervention and control GP practices, MRI was used
less than 5 times in total, which meant there were too few numbers for any meaningful comparison of MRI alone.”
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we specified that is was strictly not allowed to increase the
speed of access to physiotherapy treatment for interven-
tion participants.
The main STarT MSK trial is currently ongoing
(ISRCTN15366334).
Conclusions
This feasibility and pilot trial has successfully demon-
strated the feasibility of the cluster RCT design with
high retention rates over 6 months (> 90%) and little
evidence of selection bias, although changes to the
main trial sample size were required due to a slower
than expected recruitment rate. GP point-of-
consultation fidelity to the stratified care intervention
was mixed with GPs using the tool less often than
expected (only when they coded consultations, when
they had time and when MSK pain was the primary
reason for the visit). However, there was high fidelity
to choosing recommended matched treatment options
(> 80% of cases). The learning from this feasibility
and pilot RCT has led to a number of important
changes prior to the main STarT MSK trial testing
the clinical and cost-effectiveness of stratified primary
care for patients with MSK pain.
Table 4 Clinical outcome measures at 6-month follow-up by intervention arm
Key characteristics Intervention
6 m follow-up (n = 200)
Control
6 m follow-up (n = 258)
6-month pain intensity (self-reported), mean (SD) 3.93 (2.98) [n = 209]a 4.18 (2.88) [n = 268]a
Change in pain intensity (0–10, higher score is worse), from GP
consultation to 6-month Questionnaire, mean (SD)
−2.6 (3.1) [n = 207] −1.9 (3.1) [n = 266]
Pain interference with performance at work (0–10, the higher
score the worse), mean (SD)
3.14 (2.74) [n = 87] 3.86 (3.13) [n = 115]
Days of moderate physical activity per week, median (IQR) 3 (1–4) [n = 199] 3 (1–4) [n = 257]
Currently employed (Yes), n (%) 78 (40.2%) 101 (39.9%)
Time-off-work last 6 m due to MSK pain (Yes), n (%) 15 (17.4%) 29 (25.4%)
Overall global change (−5–5, the higher score the better), mean (SD) 1.20 (2.72) [n = 199] 1.15 (2.62) [n = 257]
Risk status using a development version of the Keele STarT
MSK Tool, mean (SD) (note: not the final version)
3.40 (2.70) [n = 190] 3.64 (2.35) [n = 234]
Low risk (0–3 score), n (%) 113 (59.5%) 127 (54.3%)
Medium risk (4–7 score), n (%) 60 (31.6%) 93 (39.7%)
High risk (8–9 score), n (%) 17 (9.0%) 14 (6.0%)
Overall musculoskeletal health status (MSK-HQ, 0–56, the higher
score the better), mean (SD)
37.5 (12.8) [n = 193] 37.3 (11.8) [n = 248]
Fear-avoidance (using 11-item TSK, higher score the worse) mean (SD) 22.81 (7.25) [n = 197] 23.70 (7.24) [n = 253]
Satisfaction with GP care for MSK pain
Very satisfied, n (%) 48 (24.2%) 58 (22.8%)
Quite satisfied, n (%) 71 (35.9%) 89 (34.9%)
No opinion, n (%) 46 (23.2%) 60 (23.5%)
Not very satisfied, n (%) 25 (12.6%) 44 (17.3%)
Not at all satisfied, n (%) 8 (4.0%) 4 (1.6%)
Knee physical function using KOOS (the higher score the better), mean (SD) 51.7 (24.5) [n = 55] 53.6 (22.9) [n = 72]
Neck physical function using NDI (the higher score the worse), mean (SD) 7.80 (5.83) [n = 27] 11.89 (11.57) [n = 24]
Back physical function using RMDQ (the higher score the worse), mean (SD) 6.90 (6.52) [n = 61] 6.44 (5.80) [n = 75]
Shoulder physical function using SPADI-Function
(the higher score the worse), mean (SD)
30.2 (29.6) [n = 44] 33.4 (27.8) [n = 62]
Multi-site physical function using SF12 PCS the higher score the better), mean (SD) 37.3 (15.1) [n = 12] 34.7 (10.7) [n = 23]
Last 6 months saw a professional for MSK pain [n = 421] 126 (67.0%) 175 (75.1%)
Last 6 months received any MSK investigation/treatment [n = 412] 66 (36.7%) 66 (28.5%)
Last 6 months had MSK hospital overnight stay [n = 446] 5 (2.6%) 6 (2.4%)
Quality of life using EQ5D-5 L, mean (SD) 0.65 (0.26) [n = 208]a 0.63 (0.25) [n = 258]a
a Additionally includes minimal data collection (MDC) responses hence the denominator numbers (n) are greater than the total column numbers of 200
(intervention) and 258 (control) which reflect total questionnaire returns
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